Burleson & Company, LLC Ultragenyx Pharmaceutical Inc. Transaction History
Burleson & Company, LLC
- $384 Million
- Q4 2022
A detailed history of Burleson & Company, LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Burleson & Company, LLC holds 10 shares of RARE stock, worth $587. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10
Previous 10
-0.0%
Holding current value
$587
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding RARE
# of Institutions
287Shares Held
88.1MCall Options Held
505KPut Options Held
198K-
Vanguard Group Inc Valley Forge, PA9.78MShares$574 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$329 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA5.35MShares$314 Million0.68% of portfolio
-
Wellington Management Group LLP Boston, MA4.56MShares$268 Million0.03% of portfolio
-
Rtw Investments, LP New York, NY3.26MShares$191 Million2.24% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $4.11B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...